Paul Ashton

Paul Ashton

Company: Inflammasome Therapeutics

Job title: CEO


Harnessing the Potential of Dual Inhibition: Targeting NLRP3 & NLRC4 Inflammasomes for Therapeutic Intervention 9:00 am

Revealing the collaboration between NLRP3 and NLRC4 inflammasomes in triggering inflammation linked to lupus, macular degeneration, Alzheimer’s, and multiple sclerosis Demonstrating the efficacy of inflammasome blockade in animal models of macular degeneration and lupus patients, promising disease prevention and inflammation reduction Exploring Phase 1 trial initiation for evaluation of Kamuvudine-8 in Geographic AtrophyRead more

day: Day 1

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.